VCEL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Vericel Corp (VCEL) does not present a strong buy opportunity for a beginner, long-term investor at this moment. While the company has shown solid financial growth and a positive revenue outlook, the technical indicators and options data suggest limited short-term upside potential. Additionally, there are no strong trading signals or recent influential purchases to support immediate action.
The MACD is positive but contracting, RSI is neutral at 57.487, and moving averages are converging, indicating no clear trend. The stock is trading near its resistance level (R1: 34.588), with a pre-market price of 33.48. Historical patterns suggest a potential decline of -0.69% in the next day and -6.92% in the next month.
Strong Q4 2025 financial performance with 23.27% YoY revenue growth and 17.35% YoY net income growth.
Analyst price target raised to $64, with a Buy rating.
The global cell therapy market is projected to grow significantly, benefiting companies like Vericel.
Options data shows a high Put-Call Open Interest Ratio (1.98), indicating bearish sentiment.
Stock trend analysis suggests a potential decline in the short term.
No significant hedge fund, insider, or congressional trading activity to support bullish sentiment.
In Q4 2025, Vericel reported a 23.27% YoY increase in revenue to $92.92M, a 17.35% YoY increase in net income to $23.24M, and a 21.21% YoY increase in EPS to $0.4. Gross margin improved slightly to 78.7%.
H.C. Wainwright raised the price target to $64 from $60, maintaining a Buy rating. The analyst expects 20% Q1 sales growth, indicating a positive outlook for the company.
